Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.9% Higher – Here’s Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price was up 8.9% during mid-day trading on Wednesday . The stock traded as high as $3.27 and last traded at $3.2350. Approximately 9,694,861 shares were traded during mid-day trading, a decline of 41% from the average daily volume of 16,502,961 shares. The stock had previously closed at $2.97.

Analysts Set New Price Targets

A number of research analysts recently weighed in on RXRX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Morgan Stanley raised their price objective on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Bank of America reduced their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Finally, Wall Street Zen lowered Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $8.10.

Recursion Pharmaceuticals Trading Up 6.9%

The firm has a 50 day simple moving average of $3.27 and a 200 day simple moving average of $3.87. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.68 billion, a PE ratio of -2.65 and a beta of 1.05.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The business had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. During the same period last year, the business posted ($0.50) EPS. The company’s revenue was down 56.8% compared to the same quarter last year. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.02 earnings per share for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 28,298 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $3.35, for a total transaction of $94,798.30. Following the sale, the chief executive officer directly owned 2,262,085 shares in the company, valued at approximately $7,577,984.75. This trade represents a 1.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Ben R. Taylor sold 7,956 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total value of $26,970.84. Following the sale, the chief financial officer owned 1,180,318 shares in the company, valued at approximately $4,001,278.02. This represents a 0.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 96,254 shares of company stock worth $320,369. Insiders own 8.43% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. ARK Investment Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 1.7% in the 3rd quarter. ARK Investment Management LLC now owns 33,545,499 shares of the company’s stock worth $163,702,000 after buying an additional 556,868 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Recursion Pharmaceuticals by 10.3% in the 3rd quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock worth $194,127,000 after buying an additional 3,708,975 shares during the last quarter. Rafferty Asset Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 110.6% in the 3rd quarter. Rafferty Asset Management LLC now owns 750,191 shares of the company’s stock worth $3,661,000 after buying an additional 394,022 shares during the last quarter. DNB Asset Management AS purchased a new position in shares of Recursion Pharmaceuticals in the 3rd quarter worth $1,531,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in shares of Recursion Pharmaceuticals by 94.8% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 1,774,995 shares of the company’s stock worth $8,662,000 after buying an additional 863,910 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.